Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

Rheumatoid Arthritis

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Arthritis Res Ther

Picchianti Diamanti A, Paci V, Luchetti Gentiloni MM, Salemi S, Sesti G, Bellofatto IA, Baldi C, Falsetti P, Chimenti MS, D'Antonio A, Crepaldi G, Zabotti A, Giovannini I, Canzoni M, Fiore D, Sebastiani GD, Scirocco C, Perricone C, Laganà B, Iagnocco A

doi: 10.1186/s13075-025-03671-z

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Rheumatoid Arthritis

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Rheumatology (Oxford)

Hiramatsu Y, Kotani T, Nakamura E, Yoshikawa A, Hashimoto M, Onishi A, Murata K, Yamamoto N, Murakami K, Hirano T, Maeda Y, Ebina K, Sendo S, Son Y, Amuro H, Hara R, Katayama M, Yamamoto W, Takeuchi T

doi: 10.1093/rheumatology/keaf558

Rheumatoid Arthritis

Towards the development of a definition of independence for individuals diagnosed with rheumatoid arthritis in remission: an 'OMERACT remission in rheumatoid arthritis patient perspective' special interest group report

Semin Arthritis Rheum

Gazel U, Barnes E, Jones B, Terrett A, Voshaar M, Hoogland W, March L, Beaton D, Khoo T, Chin A, Shea B, Tugwell P, Proudman S, Flurey CA

doi: 10.1016/j.semarthrit.2026.152948

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

BMJ Open

Rayner F, Hiu S, Melville A, Bigirumurame T, Anderson A, Dyke B, Kerrigan S, McGucken A, Prichard J, Shahrokhabadi MS, Hilkens CMU, Buckley CD, McInnes IB, Ng WF, Goodyear C, Teare D, Filer A, Siebert S, Raza K, Pratt A, Baker KF, Isaacs J

doi: 10.1136/bmjopen-2024-092478

Rheumatoid Arthritis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, Berger S, Rockwitz K, Krüger K, Schneider KM, Regierer AC, Strangfeld A

doi: 10.1016/j.ard.2025.05.014

Psoriatic Arthritis

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Adv Ther

Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF

doi: 10.1007/s12325-025-03416-z

Related content

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Towards the development of a definition of independence for individuals diagnosed with rheumatoid arthritis in remission: an 'OMERACT remission in rheumatoid arthritis patient perspective' special interest group report

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors